Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilretta in knee osteoarthritis
NCT04261049Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2020
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triamcinolone acetonide in osteoarthritis (OA), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Maximal Isometric Voluntary Contractions Normalized to Body Weight at 8 weeks, Central Activation Ratio at 8 weeks and 9 more. Started Aug 2020; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04261049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261049.